HDAC9 and ovarian carcinoma: Indeed, panobinostat, another pan-HDAC inhibitor similar to vorinostat, has shown to enhance olaparib efficacy by reducing cell proliferation, increasing DNA damage, as well as T-cell infiltration, and ultimately reducing peritoneal masses and tumor burden in a mouse model of ovarian cancer [41].